ALEMBICLTD.NSE · Alembic Limited

-

Please sign in to comment on ALEMBICLTD.NSE

1 Comment

Admin

4 years, 1 month ago

Alembic Limited is currently in a long term uptrend where the price is trading 17.9% above its 200 day moving average.

From a valuation standpoint, the stock is 1048.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 55.0.

Alembic Limited's total revenue rose by 13.5% to $145M since the same quarter in the previous year.

Its net income has increased by 25.8% to $856M since the same quarter in the previous year.

Finally, its free cash flow grew by 176.6% to $27M since the same quarter in the previous year.

Based on the above factors, Alembic Limited gets an overall score of 4/5.

Sector	Real Estate
Industry	Real Estate - Development
Exchange	NSE
ISIN	INE426A01027
CurrencyCode	INR

Dividend Yield	2.4%
Beta	0.68
Target Price	None
Market Cap	26B
PE Ratio	8.26

ABOUT

Alembic Limited

Alembic Limited engages in real estate business in India and internationally. It operates through Active Pharmaceutical Ingredient (API) and Real Estate segments. The company constructs residential and commercial real estate projects; provision of project management and marketing consultancy services; and leasing of commercial properties. It manufactures and markets fermentation and chemistry based on active pharmaceutical ingredient; and engages in research and development. In addition, it is involved in power generation through co-generation plants and wind power sources. The company serves individuals, corporates, business houses, and pharmaceutical companies. The company was founded in 1907 and is based in Vadodara, India. Alembic Limited is a subsidiary of Nirayu Pvt. Ltd.

ALEMBICLTD.NSE · Alembic Limited

-

Alembic Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Alembic Limited using a moving average strategy